Literature DB >> 7908700

Induction of a major histocompatibility complex class I-restricted cytotoxic T-lymphocyte response to a highly conserved region of human immunodeficiency virus type 1 (HIV-1) gp120 in seronegative humans immunized with a candidate HIV-1 vaccine.

R P Johnson1, S A Hammond, A Trocha, R F Siliciano, B D Walker.   

Abstract

Efforts to induce broadly reactive immunity against human immunodeficiency virus type 1 (HIV-1) have been impaired by the extent of sequence variation exhibited by this lentivirus. Cytotoxic T lymphocytes (CTL) specific for other viruses such as influenza virus have been shown to mediate immunity against divergent viral strains, a property that is related to the ability of CTL to recognize processed antigen derived from conserved viral proteins. A recent candidate HIV-1 vaccine regimen has been described in which subjects receive a primary immunization with a recombinant vaccinia virus expressing gp160 and then a booster immunization with recombinant gp160. Volunteers immunized with this regimen have exhibited augmented humoral responses and have also developed CD4+ and CD8+ CTL specific for gp160. In this report, we have identified the epitopes recognized by CD4+ and CD8+ CTL obtained from two vaccines. An immunodominant CD8+ CTL response was HLA-A3.1 restricted and recognized a 10-amino-acid epitope (gp120/38-47) in a highly conserved region of gp120. CTL specific for the epitope gp120/38-47 were able to lyse targets sensitized with peptides corresponding to all known natural sequence variants in this region. In addition, other HLA class I-restricted CTL epitopes were identified in relatively conserved regions of gp120 and gp41, and CD4+ CTL were shown to recognize two different regions of gp120. Thus, in these two volunteers, immunization with a single strain of HIV-1 induced CD4+ and CD8+ CTL that are specific for multiple conserved regions of HIV-1 and would be expected to recognize a broad range of viral isolates.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7908700      PMCID: PMC236805     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  55 in total

1.  Exact definition of species-specific and cross-reactive epitopes of the 65-kilodalton protein of Mycobacterium leprae using synthetic peptides.

Authors:  D C Anderson; M E Barry; T M Buchanan
Journal:  J Immunol       Date:  1988-07-15       Impact factor: 5.422

Review 2.  Antiviral cytotoxic T lymphocyte induction and vaccination.

Authors:  B T Rouse; S Norley; S Martin
Journal:  Rev Infect Dis       Date:  1988 Jan-Feb

3.  Class I major histocompatibility complex-restricted cytolytic T lymphocytes recognize a limited number of sites on the influenza hemagglutinin.

Authors:  T J Braciale; M T Sweetser; L A Morrison; D J Kittlesen; V L Braciale
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

4.  Group-specific, major histocompatibility complex class I-restricted cytotoxic responses to human immunodeficiency virus 1 (HIV-1) envelope proteins by cloned peripheral blood T cells from an HIV-1-infected individual.

Authors:  S Koenig; P Earl; D Powell; G Pantaleo; S Merli; B Moss; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

5.  HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides.

Authors:  D F Nixon; A R Townsend; J G Elvin; C R Rizza; J Gallwey; A J McMichael
Journal:  Nature       Date:  1988-12-01       Impact factor: 49.962

6.  Unusually high frequencies of HIV-specific cytotoxic T lymphocytes in humans.

Authors:  A Hoffenbach; P Langlade-Demoyen; G Dadaglio; E Vilmer; F Michel; C Mayaud; B Autran; F Plata
Journal:  J Immunol       Date:  1989-01-15       Impact factor: 5.422

7.  Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein.

Authors:  E L Cooney; M J McElrath; L Corey; S L Hu; A C Collier; D Arditti; M Hoffman; R W Coombs; G E Smith; P D Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

8.  HIV-1 reverse transcriptase is a target for cytotoxic T lymphocytes in infected individuals.

Authors:  B D Walker; C Flexner; T J Paradis; T C Fuller; M S Hirsch; R T Schooley; B Moss
Journal:  Science       Date:  1988-04-01       Impact factor: 47.728

9.  CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication.

Authors:  C M Walker; D J Moody; D P Stites; J A Levy
Journal:  Science       Date:  1986-12-19       Impact factor: 47.728

10.  Murine cytotoxic T lymphocyte recognition of individual influenza virus proteins. High frequency of nonresponder MHC class I alleles.

Authors:  J R Bennink; J W Yewdell
Journal:  J Exp Med       Date:  1988-11-01       Impact factor: 14.307

View more
  15 in total

1.  Frequency of HLA allele-specific peptide motifs in HIV-1 proteins correlates with the allele's association with relative rates of disease progression after HIV-1 infection.

Authors:  G W Nelson; R Kaslow; D L Mann
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

2.  Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene.

Authors:  Robert J O'Connell; Jean-Louis Excler; Victoria R Polonis; Silvia Ratto-Kim; Josephine Cox; Linda L Jagodzinski; Michelle Liu; Lindsay Wieczorek; John G McNeil; Raphaelle El-Habib; Nelson L Michael; Bruce L Gilliam; Robert Paris; Thomas C VanCott; Georgia D Tomaras; Deborah L Birx; Merlin L Robb; Jerome H Kim
Journal:  J Infect Dis       Date:  2016-02-11       Impact factor: 5.226

3.  Identification of type-specific cytotoxic T lymphocyte responses to homologous viral proteins in laboratory workers accidentally infected with HIV-1.

Authors:  N V Sipsas; S A Kalams; A Trocha; S He; W A Blattner; B D Walker; R P Johnson
Journal:  J Clin Invest       Date:  1997-02-15       Impact factor: 14.808

4.  Relative dominance of epitope-specific cytotoxic T-lymphocyte responses in human immunodeficiency virus type 1-infected persons with shared HLA alleles.

Authors:  C L Day; A K Shea; M A Altfeld; D P Olson; S P Buchbinder; F M Hecht; E S Rosenberg; B D Walker; S A Kalams
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

5.  Limited sequence evolution within persistently targeted CD8 epitopes in chronic human immunodeficiency virus type 1 infection.

Authors:  Tomohiko Koibuchi; Todd M Allen; Mathias Lichterfeld; Stanley K Mui; Kristin M O'Sullivan; Alicja Trocha; Spyros A Kalams; R Paul Johnson; Bruce D Walker
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

6.  High major histocompatibility complex-unrestricted lysis of simian immunodeficiency virus envelope-expressing cells predisposes macaques to rapid AIDS progression.

Authors:  C Yin; M S Wu; C D Pauza; M S Salvato
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

7.  T-cell receptor-mediated anergy of a human immunodeficiency virus (HIV) gp120-specific CD4(+) cytotoxic T-cell clone, induced by a natural HIV type 1 variant peptide.

Authors:  L Bouhdoud; P Villain; A Merzouki; M Arella; C Couture
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

8.  Early induction and maintenance of Env-specific T-helper cells following human immunodeficiency virus type 1 infection.

Authors:  Uma Malhotra; Sarah Holte; Tuofu Zhu; Elizabeth Delpit; Claire Huntsberry; Alessandro Sette; Raj Shankarappa; Janine Maenza; Lawrence Corey; M Juliana McElrath
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

9.  Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen.

Authors:  M Wang; V Bronte; P W Chen; L Gritz; D Panicali; S A Rosenberg; N P Restifo
Journal:  J Immunol       Date:  1995-05-01       Impact factor: 5.422

10.  Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases.

Authors:  K R Irvine; J B Rao; S A Rosenberg; N P Restifo
Journal:  J Immunol       Date:  1996-01-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.